What are the effects of microdosing with Ozempic?
Microdosing with Ozempic has not been studied, so nobody knows whether it works or is safe. If you are considering using semaglutide, discuss with your doctor which dose is appropriate for your situation.
There is not a single scientific study on microdosing with semaglutide (Ozempic). All available studies used standard therapeutic doses of 0.5 to 2.4 mg per week. On the basis of current research, it is simply impossible to make any claims about whether microdosing works, is safe, or is worthwhile.
What we do know about standard doses: in people with overweight or obesity without diabetes, semaglutide leads to an average of 5.3 kg more weight loss than a placebo. Higher doses produce greater effects than lower ones. That suggests that lower doses yield less benefit, but what that looks like at a true microdose is entirely unknown.
Side effects at standard doses are considerable. Almost half of all users experience gastrointestinal complaints: nausea, diarrhoea, reduced appetite, or vomiting. This was also the most commonly cited reason for discontinuing treatment. What the side-effect profile looks like at microdoses has not been studied.
At standard doses, semaglutide has also demonstrated benefits for the heart and kidneys in people with type 2 diabetes: fewer heart attacks, strokes, and hospitalisations for heart failure, as well as reduced protein loss through the urine. Whether this also applies at lower doses is unknown.
Microdosing with Ozempic is a phenomenon circulating on social media and in certain health circles, but it has no scientific basis. Without research, nothing can be said about the correct dose, the effect, or the safety. Anyone considering the use of semaglutide would be wise to discuss this with a doctor and not to rely on anecdotes or trends.